Biogen Inc.: New Data Presented at AD/PD 2023 Show Biogen's

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein

Related Keywords

Gothenburg , Vastra Gotalands Lan , Sweden , Cambridge , Cambridgeshire , United Kingdom , United States , Priya Singhal , Mike Hencke , Jack Cox , Youtube , Twitter , Alzheimer Association , Nasdaq , Exchange Commission , Facebook , International Conference On Alzheimer , Linkedin , Head Of Development At Biogen , International Conference , Executive Vice President , Tau Protein , Accessed March , Tau Topic , Accessed February , Diese Gold Aktie , Sichern Sie , Biogen , Data , Resented , 023 , Show , Iib080 , Apt , Substantially , Educed , Protein , Levels , Patients , Early , Stage , Lzheimer , Disease ,